Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 1998 for ISIS Pharmaceuticals, Inc. (Note: The input metadata lists "IONIS PHARMACEUTICALS INC," but the filing text explicitly identifies the registrant as ISIS Pharmaceuticals, Inc.). The company is a biopharmaceutical firm focused on research, drug discovery, and development, primarily funded through collaborative agreements, equity sales, and debt financing. The company is not yet profitable and anticipates continued operating losses.
Key Financial Metrics
| Metric | Q1 1998 | Q1 1997 |
|---|---|---|
| Total Revenue | $6.9 million | $5.6 million |
| Net Loss | $(11.5) million | $(8.6) million |
| Net Loss Per Share | $(0.43) | $(0.33) |
| Cash and Cash Equivalents | $27.8 million | $26.2 million |
| Short-term Investments | $41.7 million | N/A |
| Total Liquidity (Cash + ST Investments) | $69.5 million | N/A |
| Working Capital | $51.9 million | N/A |
| Total Debt (Current + Long-term) | $58.9 million | N/A |
| Cash Used in Operations | $(17.2) million | $(3.7) million |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 24% to $6.9 million, driven by a 26% rise in collaborative R&D revenue ($5.8 million vs. $4.6 million) and higher interest income ($1.1 million vs. $0.9 million).
- Expense Increases: R&D expenses rose 26% to $14.9 million due to increased preclinical and clinical trial activities. Interest expense surged to $1.7 million from $0.6 million, primarily due to a $25 million private debt financing completed in late 1997.
- Liquidity Decline: Cash and short-term investments decreased from $86.8 million at year-end 1997 to $69.5 million at March 31, 1998, reflecting operating losses and capital expenditures.
- Debt Accrual: Long-term debt increased slightly due to interest accrual on deferred payment loans, offset partially by principal repayments.
Guidance, Outlook, and Risks
- Outlook: Management expects operating losses to continue and increase for several years as R&D activities expand. The company believes current liquidity, combined with a $15 million follow-on debt financing completed on May 1, 1998, is sufficient to meet requirements for at least two years.
- Subsequent Events: In April 1998, the company filed a New Drug Application (NDA) for fomivirsen (CMV retinitis), triggering a $5 million milestone payment from CIBA Vision. Additionally, a $15 million private debt financing was closed on May 1, 1998, with terms similar to the 1997 financing (14% interest, maturity in 2007).
- Risks: The filing highlights risks inherent in drug discovery and development, including the uncertainty of regulatory approval and commercialization. Forward-looking statements are subject to these uncertainties.
- Legal Proceedings: The company reported no pending legal proceedings.
Investor Verification Checklist
- Verify the status and timeline of the NDA filing for fomivirsen and the receipt of the $5 million milestone payment.
- Confirm the terms and impact of the May 1, 1998, $15 million debt financing on future interest obligations.
- Monitor the burn rate of cash given the $17.2 million cash outflow from operations in Q1 1998.
- Review the progress of clinical trials driving the 26% increase in R&D expenses.
- Assess the utilization of the $40 million line of credit from Boehringer Ingelheim (outstanding balance: $22.6 million).